CA
FHTX icon

Clearstead Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Clearstead Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Buy
+9
New +$40 ﹤0.01% 3497

Other funds holding FHTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $10.6B AUM 19.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Clearstead Advisors's FHTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 9 shares worth $44. The stake represents ﹤0.01% of the portfolio and ranks #3497 among its holdings.

33 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Clearstead Advisors held 9 shares of Foghorn Therapeutics worth $44 as of Q2 2026.
  • Foghorn Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3497 holding.
  • 33 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.